Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70106 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Stefan Verheye und 19 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Cardiology, ZAS Cardiovascular Center Middelheim, Antwerp, Belgium. Hauptthemen laut MEDLINE: Sirolimus, Drug-Eluting Stents, Percutaneous Coronary Intervention, Coronary Artery Disease. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The study was funded by Elixir Medical..
Abstract (Originalsprache)
Background
DESyne BDS Plus represents a novel triple drug therapy (TRx) applied on a coronary stent platform eluting the antiproliferative drug Sirolimus along with two anticoagulants (Rivaroxaban and Argatroban) to reduce the site‐specific thrombotic risk.
Aims
To assess the feasibility and safety of this novel device against a contemporary drug‐eluting stent.
Methods
This prospective, multicenter randomized (1:1) trial included 202 patients assigned between the device group (DESyne BDS Plus) and the control group (DESyne X2). A subgroup of 58 patients underwent imaging follow‐up at 6 months. The blood pharmacokinetics of Sirolimus and both anticoagulants were assessed in 11 nonrandomized patients.
Results
The primary endpoint, target lesion failure (TLF) at discharge or 3‐day postprocedure, whichever occurred first, was 0.0% (0/98) in the device and 5.0% (5/100) in the control group ( p noninferiority < 0.001). The secondary endpoint, late lumen loss at 6 months, was 0.14 mm [90% CI: 0.06; 0.23] and 0.09 mm [90% CI: 0.01; 0.18] in the device ( n = 28) and control group ( n = 27), respectively ( p noninferiority < 0.001). Through 24 months, stent thrombosis (definite/probable) was 0.0% (0/97) versus 1.0% (1/96) in the control, p = 0.497, and TLF was 2.1% (2/97) versus 11.3% (11/97), p = 0.010, respectively. Optical coherence tomography findings including strut coverage and neointimal hyperplasia thickness/volume were similar between the groups. The pharmacokinetic study indicated median maximum blood concentrations (C max ) of Rivaroxaban and Argatroban of 1.38 ng/mL and 1.99 ng/mL, respectively.
Conclusions
This is the first clinical evidence of the feasibility of site‐specific antithrombotic therapeutic with two anticoagulants and an antiproliferative mTOR inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interventional Cardiology, ZAS Cardiovascular Center Middelheim, Antwerp, Belgium.
- Department of Cardiology, Ziekenhuis Oost-Limburg, Campus Sint Jan, Genk, Belgium.
- Department of Cardiovascular Medicine, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
- Instituto Dante Pazzanese, São Paulo, Brazil.
- Cardiovascular Unit, North Shore Hospital, Auckland, New Zealand.
- Heart Center, Catharina Hospital, Eindhoven, the Netherlands.
ORCID-Profile: Stefan Verheye, Johan Bennett, Mark Webster
Förderung
- The study was funded by Elixir Medical.
Zitieren
APA
Verheye, S., Ferdinande, B., Bennett, J., Staico, R., El-Jack, S., Tonino, P. A. L., Abizaid, A., Buysschaert, I., Scott, D., Menon, M., Wilkins, G., McClean, D., Kovarnik, T., Christians, U., Neylon, A., Mehmedbegovic, Z., Smits, P. C., Morice, M. C., Webster, M., & DESyne BDS Plus RCT Investigators (2025). Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70106
Vancouver
Verheye S, Ferdinande B, Bennett J, Staico R, El-Jack S, Tonino PAL, et al. Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70106
BibTeX
@article{Verheye2025,
author = {Verheye, Stefan and Ferdinande, Bert and Bennett, Johan and Staico, Rodolfo and El-Jack, Seif and Tonino, Pim A L and Abizaid, Alexandre and Buysschaert, Ian and Scott, Douglas and Menon, Madhav and Wilkins, Gerard and McClean, Dougal and Kovarnik, Tomas and Christians, Uwe and Neylon, Antoinette and Mehmedbegovic, Zlatko and Smits, Pieter C and Morice, Marie-Claude and Webster, Mark and DESyne BDS Plus RCT Investigators, DESyne BDS Plus RCT Investigators},
title = {Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70106}
}
EUVIMED